{"id":481003,"date":"2021-04-23T07:03:21","date_gmt":"2021-04-23T11:03:21","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-to-present-new-heart-transplant-data-at-the-international-society-for-heart-and-lung-transplantation-annual-meeting\/"},"modified":"2021-04-23T07:03:21","modified_gmt":"2021-04-23T11:03:21","slug":"caredx-to-present-new-heart-transplant-data-at-the-international-society-for-heart-and-lung-transplantation-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-to-present-new-heart-transplant-data-at-the-international-society-for-heart-and-lung-transplantation-annual-meeting\/","title":{"rendered":"CareDx to Present New Heart Transplant Data at the International Society for Heart and Lung Transplantation Annual Meeting"},"content":{"rendered":"

\nRenowned transplant clinicians to present 15 heart abstracts at ISHLT
\n<\/h2>\n
\n

SOUTH SAN FRANCISCO, Calif., April 23, 2021 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced experts will present its latest heart research, which was accepted at the International Society for Heart and Lung Transplantation (ISHLT) Annual Meeting & Scientific Sessions, set to take place between April 24-28, 2021.<\/p>\n

CareDx\u2019s offerings are showcased through 22 abstracts throughout the ISHLT program. These data selected by the ISHLT organizers, will be presented by prominent thought leaders, highlighting the continued leadership in the cardiothoracic space. Additionally, a CareDx symposium will spotlight leaders in the field of heart and lung transplantation delivering cutting edge content on HeartCare, AlloMap\u00ae<\/sup>, AlloSure\u00ae<\/sup> Heart, and RemoTraC.<\/p>\n

\u201cCareDx has been a great partner for heart transplantation for so many years, and I\u2019m thrilled to be a part of their continuous innovation in patient care related to heart rejection detection,\u201d said\u00a0Mario Deng, M.D., F.A.C.C., F.E.S.C., UCLA Health.<\/p>\n

CareDx will present its virtual symposium: \u201cHeartCare: The Utility of Multi-Modality in Transplant Patient Care\u201d<\/strong> on Sunday, April 25 from 11:30 a.m. to 12:30 p.m. Eastern Time.<\/p>\n

This session will provide insights on HeartCare, the combination of AlloMap and AlloSure Heart, including the evolution of patient specific biomarkers, data supporting utility in CMV and CAV, and patient case studies.<\/p>\n

\n Speakers include:<\/strong>
\n
Mario Deng, M.D., F.A.C.C., F.E.S.C., UCLA Health
Brett Sperry, M.D., Saint Luke\u2019s Health System
Heddy Luise Holzhauser, M.D., F.A.C.C., Penn Medicine
Manreet Kanwar, M.D., Allegheny Health<\/p>\n

\u201cThis year marks our most successful ISHLT abstract session to-date\u2014with an unprecedented 15 heart abstracts and 7 lung abstracts accepted,\u201d said Reg Seeto, President and CEO, CareDx. \u201cThese abstracts underscore and showcase the value our diagnostic surveillance tools provide for heart and lung transplant recipients.\u201d<\/p>\n

The following heart transplant abstracts will be presented:<\/p>\n